Conditions: Rheumatoid Arthritis
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 208
Healthy volunteers: no

Brief summary:
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX3305 versus a placebo control in subjects with active rheumatoid arthritis on stable methotrexate therapy.

Detailed description:

Arms:
arm 1: A low dose of LX3305; daily oral intake for 12 weeks arm 2: A mid dose of LX3305; daily oral intake for 12 weeks arm 3: A high dose of LX3305; daily oral intake for 12 weeks arm 4: Matching placebo dosing with daily oral intake for 12 weeks

Interventions: intervention 1: LX3305 low dose intervention 2: LX3305 mid dose intervention 3: LX3305 high dose intervention 4: Placebo
Intervention descriptions: intervention 1: A low dose of LX3305; daily oral intake for 12 weeks intervention 2: A mid dose of LX3305; daily oral intake for 12 weeks intervention 3: A high dose of LX3305; daily oral intake for 12 weeks intervention 4: Matching placebo dosing with daily oral intake for 12 weeks

Protocol document: